Iruplinalkib Tablets as Postoperative Adjuvant Therapy in Stage IA ALK-positive NSCLC With High-risk Factors

NCT07330076 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

DRUG: Iruplinalkib tablets

Sponsor

Tianjin Medical University Cancer Institute and Hospital